Osteosarcoma in patients over 50 years of age: Multi-institutional retrospective analysis of 104 patients
| Autor: | Norifumi Naka, Masami Hosaka, Satoshi Tsukushi, Takeshi Okamoto, Kunihiro Asanuma, Seiichi Matsumoto, Ryohei Yokoyama, Tsukasa Yonemoto, Tadahiko Kubo, Kenji Sato, Yoshihiro Nishida, Teruya Kawamoto, Hiroaki Hiraga, Toshiyuki Kunisada, Akihito Nagano, Makoto Emori, Yoshihiro Matsumoto, Hideo Morioka, Hideki Yoshikawa, Kazuhiro Tanaka, Tatsuya Takagi, Koji Hiraoka, Mitsuru Takahashi, Toshifumi Ozaki, Yukihide Iwamoto, Tomotake Okuma, Hiroyuki Kawashima, Akira Kawai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Bone Neoplasms 03 medical and health sciences 0302 clinical medicine medicine Retrospective analysis Humans Orthopedics and Sports Medicine In patient Retrospective Studies Clinical Oncology Osteosarcoma 030222 orthopedics Univariate analysis Chemotherapy business.industry Age Factors Soft tissue Retrospective cohort study Middle Aged medicine.disease Neoadjuvant Therapy Surgery Survival Rate Chemotherapy Adjuvant business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Orthopaedic Science. 25:319-323 |
| ISSN: | 0949-2658 |
| Popis: | Background Primary osteosarcoma in elderly patients are rare malignant tumors. Its optimal treatment has not yet been determined. Methods This retrospective study included 104 patients aged >50 years with resectable, non-metastatic osteosarcoma treated by the members of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. The effects of adjuvant chemotherapy were estimated by comparing outcomes in patients who received surgery plus chemotherapy with those who underwent surgery alone. Results Median age at presentation was 59 years. Neoadjuvant and adjuvant chemotherapy was administered to 83 (79.8%) patients. Patients who underwent surgery plus chemotherapy and those who underwent surgery alone had 5-year overall survival (OS) rates of 68.6% and 71.7%, respectively (p = 0.780), and 5-year relapse free survival (RFS) rates of 48.2% and 43.6%, respectively (p = 0.64). Univariate analysis showed that resection with wide margins was significantly correlated with better prognosis. Conclusions The addition of chemotherapy to surgery did not improve OS or RFS in patients aged >50 years with resectable, non-metastatic osteosarcoma. Surgery with wide margins was only significantly prognostic of improved survival. The effect of chemotherapy in elderly osteosarcoma patients was unclear. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|